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Abstract
Cyclophosphamide (CP) is a chemotherapy used in combinations that are associated with cognitive impairment. In the
present study male Lister-hooded rats (n=12) were used to investigate the effects of chronic administration of CP (30mg/
kg, 7 i.v. doses, or an equivalent volume of saline) on performance in the novel location recognition (NLR) task and on the
proliferation and survival of hippocampal cells. The survival of hippocampal cells dividing at the beginning of treatment was
significantly reduced by CP. However, no difference was seen between CP treated and control groups for the number of
cells proliferating 7 days after the final injection and both groups performed equally well in the NLR task. These results
indicate that the given dose of CP acutely reduces the survival of newly born hippocampal cells. However, it does not have a
longer term effect on spatial working memory or hippocampal proliferation, suggesting that CP is less neurotoxic than
other chemotherapies with which it is used in combination.
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Introduction
Patients who have received adjuvant chemotherapy as part of
their treatment for cancer often report problems in cognition,
encompassing memory impairment, a short concentration span
and general confusion [1]. These effects can last up to several years
after completion of the treatment [2,3]. However combination
therapies are often used in clinical treatment, so the actions of
individual drugs are unclear.
In a recent review of rodent models of the cognitive effects of
chemotherapy by Seigers and Fardell [4], the majority of
investigations found that chemotherapy has a negative effect on
different aspects of learning and memory. However a small
number found that chemotherapy has no effect on cognition [5,6]
and one even reported an improvement [7]. Furthermore, many
of these studies also found that chemotherapy reduced prolifer-
ation of neural progenitors in the dentate gyrus (DG) of the
hippocampus [8,9,10]. This reduction in hippocampal neurogen-
esis has been considered as one possible cause of the cognitive
impairment seen. Throughout life, neuronal progenitors in the
subgranular zone of the DG divide to produce new neurones,
which get integrated into existing neural circuits [11] and are
thought to have a functional role in learning and memory
consolidation [12,13]. Ablation of neurogenesis by means of
irradiation [14], hippocampal lesions [15,16] or cytotoxic drugs
[17,18] has been shown to cause impairment in cognition.
Cyclophosphamide (CP), methotrexate and 5-fluorouracil
(CMF) are all chemotherapy drugs, commonly used in combina-
tion to treat breast cancer [19]. This combination is reported to
have an effect on cognition in human studies [20,21,22]. Previous
work has shown that both methotrexate and 5-fluorouracil have a
negative effect on memory and proliferation in the hippocampus
[9,23,24] and the present study focuses on the effects of CP.
CP is an alkylating agent, with its metabolites causing alkyl
crosslinks within and between DNA strands of dividing cells,
causing them to apoptose [25]. It is able to cross the blood brain
barrier [26]. In the present study CP was administered chronically
in a rat model to mimic clinical administration. A dosage of 30mg/
kg was chosen which is sufficient to cause weight loss but well
below the predicted median lethal dose of 200mg/kg [27] and
below the amount administered which causes pain or cystitis [28].
One study showed CP had an increase in antiprolific action and
less toxicity when adult rats were dosed at 14.00 h compared with
8.00 h [29], so in the present study all injections were administered
between 14.00 and 16.00 h.
In the present study, the novel location recognition (NLR) task
[30] was used to test spatial memory 6 days after the final CP
injection. Ki67 is a protein which is expressed in all stages of the
cell cycle [31] and was used to quantify cells which were
proliferating in the DG at the end of the experiment. To
investigate the effect of CP on the survival of newly generated
hippocampal cells, bromodeoxyuridine (BrdU) was injected at the
beginning of CP treatment to be incorporated into cells
proliferating at that time. The surviving cells which expressed
BrdU at the end of the experiment were quantified.
Materials and Methods
Ethics statement
Principles of laboratory animal care in this study were in
accordance to UK Home Office Guidance regulations, within the
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21445‘‘moderate’’ severity band, with approval from the University of
Nottingham ethical committee board under permit number 40/
2715. Throughout the experiment, discomfort to animals was kept
to an absolute minimum. Animals remained in good health
throughout the study and never dropped more than 10% of their
highest body weight.
Animals and treatment
Male Lister-hooded rats (125–150g; Charles River, UK) were
administered CP (30mg/kg, 7 i.v. doses, each 2 days apart, into
the tail vain , at a volume of 1.5ml/kg, dissolved in 0.9% sterile
saline; Sigma Aldrich, UK) or equivalent volume of 0.9% sterile
saline (both groups n=12). Immediately after the first injection,
BrdU was administered to both groups (250mg/kg, i.p., at a
volume of 5ml/kg; Sigma Aldrich, UK). All injections were given
under isofluorane anaesthesia.
Rats were housed in cages of four and maintained with a 12 h
light/dark cycle (7.00/19.00 h) and food and water was provided
ad libitum. They were weighed daily from arrival and allowed to
habituate for 2 weeks prior to drug administration.
NLR spatial working memory task
The NLR test was adapted from Dix and Aggleton [30] and
commenced 5 days after the final CP injection as described by
Lyons et al. [8]. In brief, rats were habituated to an arena for 30
min, 24 h prior to testing and for a further 3 min, 5 min prior to
familiarization trial. In the 3 min familiarisation trial, rats were
placed in the arena to explore two identical objects in different
locations. Rats were removed for a 15 min retention period and
then reintroduced to the arena for the 3 min choice trial in which
one object had been moved to a different location. Exploration
time of both objects in both trials was recorded blind twice and
averaged using a stopwatch from digitised recordings.
Brain tissue preparation and immunohistochemistry
The day after behavioural testing was completed, rats were put
down by rapid stunning and cervical dislocation. Tissue
preparation and staining for BrdU and Ki67 was performed as
described in Lyons et al. [8]. Briefly, brains were removed and
cryopreserved in 30% sucrose solution at 4uC then snap frozen.
Microtome sections (20 mm) were stored at 220uC until used for
immunohistochemistry.
Every 20
th section throughout the entire length of the dentate
gyrus was selected [32]. Briefly, sections were incubated with
polyclonal sheep BrdU primary antibody (1:100; Abcam, UK)
overnight followed by Alexa 488 donkey anti-sheep secondary
antibody (1:300; Invitrogen, UK) or with monoclonal mouse Ki67
primary antibody (1:100; Vector laboratories, UK) for 1 h,
followed by 1 h incubation with Alexa 555 donkey anti-mouse
(1:300; Invitrogen, UK). Sections were mounted with media
containing (diamidinophenylindole) DAPI (1.5 mg/ml) nuclear
marker (Vector laboratories, UK).
BrdU and Ki67 positive cells which co-localised with the DAPI
nuclear staining within the SGZ of both hippocampal blades were
counted on a fluorescence microscope at |40 magnification. By
combining cell counts per section for the whole dentate gyrus and
multiplying by 20, the total number of co-stained cells was
estimated [33]. All counting was performed blind.
Statistical analysis
Statistical analysis and graphs were created using GraphPad
Prism 5 and significance was regarded as p,0.05. Body weight was
analysed using two-way repeated measured ANOVA. Student’s
paired t tests were used to compare exploration times of animals in
the familiarisation and choice trials. Preference indices (PI) were
created by expressing time spent exploring the object in the novel
location as a percentage of the sum of exploration time of novel
and familiar locations in the choice trial, to create a single value to
compare between groups [17]. PI was compared to 50% chance
using a one-sample t test. Student’s unpaired t tests were used to
compare PI, total exploration time and cells counts between the
groups.
Results
Both treatment and time had a significant effect on body weight
(F1,418=5.51, p,0.05 F19,418=367.9, p,0.0001 respectively, two-
way repeated measures ANOVA, Figure 1) and a significant effect
of treatment 6 time interaction was also confirmed
(F19,418=30.23, p,0.0001). Animals remained in good health
throughout the study and never dropped more than 10% of their
highest body weight.
The NLR task was used to test cognition and Student’s paired t
tests were used to compare exploration times of the objects. In the
familiarisation trial, neither the vehicle nor CP treated group
explored the objects in locations A or B for significantly different
lengths of time, showing no preference for either location (p.0.05,
Figure 2a). In the choice trial, both groups preferentially explored
the object in the novel location (p,0.05, Figure 2b), indicating no
memory impairment. The raw exploration time data was
converted into PI for further analysis (Figure 2c). A Student’s
unpaired t test revealed no significant difference between the PI of
the vehicle and CP treated groups (p.0.05) and PI of both groups
significantly differed from 50% chance (both p,0.05), indicating
neither group had impaired cognition. No difference was found in
total exploration time of the vehicle and CP treated groups
(p.0.05 Figure 2d).
BrdU was injected on the day of the first CP/saline injection to
investigate the survival of the cells which were dividing at that
time. Animals receiving CP had significantly fewer BrdU-positive
cells in the DG (p,0.05, Student’s unpaired t test, Figure 3a). The
most likely explanation for this is that CP treatment reduced the
survival of the cells which were dividing at the start of treatment.
Alternatively, it is possible that CP might have transiently
increased the rate of proliferation of these hippocampal cells,
causing the BrdU to become diluted and undetectable. No
significant difference was found between groups for the amount of
Ki67-positive cells in the DG (p.0.05, unpaired Student’s t test,
Figure 3b), suggesting that CP does not affect cells dividing in the
DG 7 days after the final injection.
Figure 1. Body weights. Body weights of rats (mean 6 SEM)
throughout the study. Arrows indicate CP (30mg/kg)/saline injections.
doi:10.1371/journal.pone.0021445.g001
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In the present study a rat model was used to investigate the
effects of CP on cognition and the survival and proliferation of
newly generated hippocampal cells.
The NLR task was chosen to test spatial working memory, as it
is hippocampal dependent [34] and it does not rely on any positive
or negative reinforcers which may confound results. The results
showed that animals who had received a series of CP injections
were still able to distinguish an object in a novel location from that
in a familiar, so did not differ from the control group. This
indicates that the dose and administration of CP used in the
present study did not affect the rats’ ability in this task. Other
studies using rodent models within the literature have shown a
mixture of results in regard to the effect of CP on cognition. Lee at
al. [7] found that 4, 100mg/kg doses of CP, 4 weeks apart, caused
an improvement in Morris water maze performance in rat.
However, other authors giving 4 weekly doses of 25mg/kg CP
found an impairment in a passive avoidance test a week after
treatment in female rats [35]. Furthermore, Macleod et al. [6]
found a sub-chronic weekly dose of 40mg/kg of CP impaired
context specific, but not cue specific conditioned emotional
response in rat a week after the final injection. These differences
may be explained by the different dosages and different
behavioural tests used. It would be interesting to use further
behavioural tests to investigate the effect of dosing regimen used in
the present study on different cognitive domains in rat. Studies on
mice have found an acute affect (within 24 hours) on memory but
Figure 2. Novel location recognition (NLR) task. Mean exploration times (mean 6 SEM) of the rats for each object in the familiarisation (a) and
choice (b) trials of the NLR task. There was no significant difference in exploration time of either object for both groups in the familiarisation trial
(p.0.05). In the choice trial, both groups spent significantly longer exploring the object in the novel location (p,0.05). Preference indices (PI, (c),
mean 6 SEM) were created by expressing time spent exploring the object in the novel location as a percentage of the sum of exploration time of
novel and familiar locations in the choice trial (Bruel-Jungerman et al. 2005). Both groups were significantly different from chance (p,0.05). The total
exploration time (mean 6 SEM) for both trial combined (d) did not differ significantly between groups (p.0.05).
doi:10.1371/journal.pone.0021445.g002
Figure 3. BrdU and Ki67-positive cell counts. Total number of BrdU -positive (a) and Ki67-positive (b) cells in the dentate gyrus (mean 6 SEM)
estimated from cell counts. Rats receiving CP had significantly fewer BrdU-positive cells (p,0.05) than the saline-treated control group. No significant
difference was found between groups for the total numbers of Ki67-positive cells.
doi:10.1371/journal.pone.0021445.g003
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study demonstrate that CP causes no deficit in the NLR task 6
days after the final CP injection. However this does not preclude
the possibility that CP may have acute effects on memory which
recover over a short time period. It is also possible that CP may
have longer term effects which have not been examined in the
present study.
New neurons in the DG have been shown to be preferentially
used in spatial learning tasks [38] and reductions in DG
neurogenesis impair the ability of animals to perform these tasks
[39]. It is estimated that over 80% of dividing cells in the
subgranular are destined to become dentate gyrus neurones [40].
In the present study, the number of cells proliferating (Ki67-
positive) in the subgranular zone of the DG, a week after the final
injection, was not affected by CP compared to the control group,
although the number of BrdU-positive cells was significantly
reduced. This reduction suggests that the survival of the cells
which were dividing at the beginning of the experiment was lower
in rats that received CP, indicating the drug is cytotoxic to newly
generated hippocampal cells. This might be an explanation for the
acute effects on behaviour found in some studies [36,37]. This
conclusion is in line with recent studies showing that cell
proliferation is reduced the day after CP administration [26] but
gradually recover over the following days [36], correlating with
cognitive performance.
It would be interesting to look at the effects of CP on cognition,
cell proliferation and survival over a longer time period as another
alkylating agent, thioTEPA, caused an initial reduction in
hippocampal cell proliferation in mice, followed by a transient 3
week recovery. This in turn was followed by a long term deficiency
in cell proliferation lasting for 3 months and these deficiencies
were roughly correlated with spatial cognitive decline [41].
Collectively, the results of different studies of CP on cognition
and neurogenesis, still do not paint a clear picture. Drug delivery,
with respect to route of administration, dosage and time course has
differed between studies as have the behavioural tests used.
Evidence from the previous studies suggests that CP may have an
acute effect on cells proliferating in the subgranular zone of the
adult DG during which time animals may display cognitive
deficits. However, it appears likely that the reduction in cell
proliferation and spatial cognition is subtle and reversible. CP is
broken down by aldehyde dehydrogenase 3 present in the brain
which converts CP into non-toxic metabolites [42]. The presence
of this enzyme may make the effects of CP relatively short lasting
compared with other chemotherapy agents.
CP is often administered with methotrexate and 5-fluorouracil,
a combination known as CMF. This drug cocktail has been
associated with cognitive impairment in patient studies [20,21]
and several rodent models have been used to investigate the
individual drugs. In the majority of studies, 5-fluorouracil has been
shown to chronically impair memory and reduce proliferation in
the DG of the hippocampus for weeks after treatment has ended
[9,43,44]. Likewise, the negative effect of methotrexate on
cognition and proliferation has also been shown to last for weeks
[5,8,24,44]. Indeed, previous experiments within our laboratory
have shown that both 5-fluorouracil and methotrexate cause rats
to be impaired in the NLR task used in the present study and
reduce both the proliferation and survival of hippocampal cells
[8,9]. If these results are translatable to humans, they suggest that
although CP may acutely impair spatial cognition and reduce the
survival of newly generated hippocampal cells, this is reversible in
a matter of several days and it is likely to be other chemotherapy
drugs causing the longer-term impairment.
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